West Pharmaceutical Services, Inc. (WST)
NYSE: WST · Real-Time Price · USD
271.04
-4.30 (-1.56%)
Nov 7, 2025, 4:00 PM EST - Market closed
WST Stock Forecast
Stock Price Forecast
The 8 analysts that cover WST stock have a consensus rating of "Strong Buy" and an average price target of $354.5, which forecasts a 30.79% increase in the stock price over the next year. The lowest target is $311 and the highest is $400.
Price Target: $354.5 (+30.79%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for WST stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Initiates $350 | Strong Buy | Initiates | $350 | +29.13% | Oct 29, 2025 |
| Barclays | Barclays | Hold Maintains $275 → $325 | Hold | Maintains | $275 → $325 | +19.91% | Oct 27, 2025 |
| UBS | UBS | Strong Buy Maintains $320 → $355 | Strong Buy | Maintains | $320 → $355 | +30.98% | Oct 24, 2025 |
| Keybanc | Keybanc | Buy Maintains $325 → $350 | Buy | Maintains | $325 → $350 | +29.13% | Oct 24, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $350 → $390 | Buy | Maintains | $350 → $390 | +43.89% | Oct 23, 2025 |
Financial Forecast
Revenue This Year
3.10B
from 2.89B
Increased by 6.97%
Revenue Next Year
3.28B
from 3.10B
Increased by 6.11%
EPS This Year
7.16
from 6.69
Increased by 7.07%
EPS Next Year
7.77
from 7.16
Increased by 8.46%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2B | 3.5B | |||
| Avg | 3.1B | 3.3B | |||
| Low | 3.0B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.4% | 12.4% | |||
| Avg | 7.0% | 6.1% | |||
| Low | 3.6% | 1.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.49 | 8.30 | |||
| Avg | 7.16 | 7.77 | |||
| Low | 6.93 | 7.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.9% | 15.8% | |||
| Avg | 7.1% | 8.5% | |||
| Low | 3.6% | 1.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.